Alliance to Identify Potential Antimicrobials

(San Diego, CA, USA). The collaboration will combine the extensive natural products library of bioLeads with Elitra's antimicrobial discovery technologies.

To identify potential new antibacterial and antifungal drugs, Elitra will contribute proprietary drug targets, related cell-based assays, and high-throughput screening capabilities, while BioLeads will contribute its library of natural products and its chemistry capabilities. Elitra retains the worldwide marketing rights for all collaboration compounds, while agreeing to make milestone payments and royalties to bioLeads for successful programs.

"More than 99% of all soil microorganisms are still unknown and represent the biotechnologic natural resource of the 21st century,” said F. G. Hansske, CEO of bioLeads. "As a highly specialized company producing potential active natural compound libraries from microorganisms, bioLeads provides an extensive unexploited substance pool.”




Related Links:
BioLeads
Elitra